Company profile for Neutrolis

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis’ lead program targets Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the innate immune system and play an important role in chronic and acute diseases. Based in Cambridge, MA, Neutrolis was founded by two of the earliest and most cited leaders in the NETs fie...
Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis’ lead program targets Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the innate immune system and play an important role in chronic and acute diseases. Based in Cambridge, MA, Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and is supported by seasoned business leaders. The company’s pipeline includes NTR-441 and NTR-10 that effectively removes NETs and halt their pathologic effects.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
c/o LabCentral 700 Main Street, North Cambridge, MA 02139
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Product Expo West

Natural Product Expo West

Not Confirmed

envelop Contact Supplier

Natural Product Expo West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/02/23/3242690/0/en/Neutrolis-Appoints-Mikael-Dolsten-M-D-Ph-D-to-Board-of-Directors-as-Executive-Director.html

GLOBENEWSWIRE
23 Feb 2026

https://www.globenewswire.com/news-release/2025/10/29/3176704/0/en/Neutrolis-Presented-First-in-Human-Proof-of-Concept-Data-Validating-DNASE1L3-Mediated-Neutrophil-Extracellular-Trap-NET-Clearance-as-a-Therapeutic-Approach-in-Autoimmunity-at-Ameri.html

GLOBENEWSWIRE
29 Oct 2025

https://www.globenewswire.com/news-release/2025/10/13/3165746/0/en/Neutrolis-Announces-Late-Breaking-Oral-Presentation-of-Clinical-Results-at-American-College-of-Rheumatology-Convergence-2025.html

GLOBENEWSWIRE
13 Oct 2025

https://www.globenewswire.com/news-release/2024/12/23/3001191/0/en/Neutrolis-Licenses-University-of-Illinois-Chicago-Patent-to-Advance-Topical-Dry-Eye-Disease-Therapy-Targeting-NETs.html

GLOBENEWSWIRE
23 Dec 2024

https://www.globenewswire.com/news-release/2024/12/18/2999013/0/en/Neutrolis-Expands-Senior-Leadership-Team-to-Drive-Development-of-Growing-Pipeline-of-Non-Immunosuppressive-Therapies-for-NET-mediated-Autoimmune-Diseases.html

GLOBENEWSWIRE
18 Dec 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty